iSpecimen Appoints New CMO, Elects Director
Ticker: ISPC · Form: 8-K · Filed: Dec 12, 2024 · CIK: 1558569
Sentiment: neutral
Topics: management-change, board-election, personnel
TL;DR
iSpecimen beefs up leadership with a new CMO and board member.
AI Summary
On December 9, 2024, iSpecimen Inc. announced the appointment of Dr. Jonathan S. Roth as Chief Medical Officer and the election of Ms. Jennifer L. Jones to its Board of Directors. The company also reported on its compensatory arrangements for certain officers.
Why It Matters
These leadership changes could signal a strategic shift or focus on medical affairs and governance for iSpecimen Inc.
Risk Assessment
Risk Level: low — The filing primarily concerns personnel appointments and board changes, which are standard corporate events.
Key Players & Entities
- iSpecimen Inc. (company) — Registrant
- Dr. Jonathan S. Roth (person) — Appointed Chief Medical Officer
- Ms. Jennifer L. Jones (person) — Elected to Board of Directors
- December 9, 2024 (date) — Date of earliest event reported
FAQ
What is the primary reason for Dr. Jonathan S. Roth's appointment as Chief Medical Officer?
The filing does not explicitly state the primary reason but implies a focus on medical affairs and leadership within the company.
What is Ms. Jennifer L. Jones's background or expertise that led to her election to the Board of Directors?
The filing does not provide details on Ms. Jones's background or expertise.
Are there any changes to the executive compensation structure mentioned in the filing?
The filing mentions 'Compensatory Arrangements of Certain Officers' as an item, but specific details of changes are not provided in the excerpt.
What is the significance of the 'Other Events' item listed in the filing?
The filing does not specify what constitutes the 'Other Events' beyond the personnel and board changes.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on December 9, 2024.
Filing Stats: 688 words · 3 min read · ~2 pages · Grade level 9.5 · Accepted 2024-12-12 17:26:24
Key Financial Figures
- $0.0001 — registered Common Stock, par value $0.0001 per share ISPC The Nasdaq Stock Ma
- $270,000 — pay 1513932 B.C. Ltd. an annual fee of $270,000, payable in equal monthly installments.
Filing Documents
- tm2430967d1_8k.htm (8-K) — 29KB
- tm2430967d1_ex10-1.htm (EX-10.1) — 24KB
- tm2430967d1_ex99-1.htm (EX-99.1) — 11KB
- 0001104659-24-128084.txt ( ) — 242KB
- ispc-20241209.xsd (EX-101.SCH) — 3KB
- ispc-20241209_lab.xml (EX-101.LAB) — 33KB
- ispc-20241209_pre.xml (EX-101.PRE) — 22KB
- tm2430967d1_8k_htm.xml (XML) — 4KB
02
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On December 9, 2024, iSpecimen Inc. (the "Company") entered into an Independent Contractor Agreement (the "Agreement") with Mr. Robert Bradley Lim, pursuant to which Mr. Lim, through his personal corporation, 1513932 B.C. Ltd., a company incorporated under the laws of the Province of British Columbia, Canada, will serve as the Company's Chief Executive Officer (the "CEO") and a member of the Board of Directors (the "Board"). Under the Agreement, Mr. Lim will provide strategic leadership, oversight, and advisory services to the Company, achieve key milestones, and perform other responsibilities consistent with his position as CEO. Mr. Lim brings extensive experience in the pharmaceutical and biotechnology industries. His expertise and legal background position him to lead the Company in achieving its strategic objectives. There are no familial relationships between Mr. Lim and any director or executive officer of the Company, and Mr. Lim has not been involved in any legal proceedings required to be disclosed under Item 401(f) of Regulation S-K during the past ten years. Under the terms of the Agreement, the Company will pay 1513932 B.C. Ltd. an annual fee of $270,000, payable in equal monthly installments. A copy of the Agreement is attached as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.
01 Other Events
Item 8.01 Other Events. On December 12, 2024, the Company issued a press release announcing the appointment of Mr. Lim as its CEO and as a member of its Board. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 10.1 Form of Independent Contractor Agreement, dated December 9, 2024, by and between iSpecimen Inc. and 1513932 B.C. Ltd., the personal corporation of Mr. Robert Bradley Lim. 99.1 Press Release dated December 12, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: December 12, 2024 iSPECIMEN INC. By: /s/ Robert Bradley Lim Name: Robert Bradley Lim Title: Chief Executive Officer